Latest Intellectual Property News

ClearVue Technologies has secured key manufacturing and distribution agreements across the Middle East, China, and the UK, while acquiring ROOTS Sustainable Agricultural Technologies to bolster its net zero ag-tech solutions.

Appen's Q4 FY24 results reveal a robust 37% revenue increase excluding Google, alongside improved EBITDA profitability, driven by generative AI projects and strategic cost management.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Volt Resources exceeded its graphite production goals in Q4 2024, producing over 800 tonnes at its Ukrainian Zavalievsky mine, while progressing development of its Tanzanian Bunyu Graphite Project and refining a novel US-based purification process.

Anax Metals has confirmed the success of its scaled-up bioleaching technology, achieving copper recoveries of up to 80% and zinc recoveries exceeding 90%, reinforcing its strategic position in Pilbara's base metals sector.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.